Literature DB >> 30485651

Can youth at high risk of illness progression be identified by measures of rumination and sleep-wake disturbance.

Ashlee B Grierson1, Jan Scott1,2, Nick Glozier1, Ian B Hickie1, Paul G Amminger3,4, Eoin Killackey3,4, Patrick D McGorry3,4, Christos Pantelis5, Lisa Phillips6, Elizabeth Scott1,7, Alison R Yung8,9, Rosemary Purcell3,4.   

Abstract

AIM: Clinical staging models offer a useful framework for understanding illness trajectories, where individuals are located on a continuum of illness progression from stage 0 (at-risk but asymptomatic) to stage 4 (end-stage disease). Importantly, clinical staging allows investigation of risk factors for illness progression with the potential to target trans-diagnostic mechanisms at an early stage, especially in help-seeking youth who often present with sub-threshold syndromes. While depressive symptoms, rumination and sleep-wake disturbances may worsen syndrome outcomes, the role of these related phenomena has yet to be examined as risk factors for trans-diagnostic illness progression in at-risk youth.
METHODS: This study is a prospective follow-up of 248 individuals aged 12 to 25 years presenting to headspace services with sub-threshold syndromes (stage 1) classified under the clinical staging model to determine transition to threshold syndromes (stage 2). Factor analysis of depression, rumination and sleep-wake patterns was used to identify key dimensions and any associations between factors and transition to stage 2 at follow-up.
RESULTS: At 1 year, 9% of cases met criteria for stage 2 (n = 22). One of three identified factors, namely the factor reflecting the commonalities shared between rumination and sleep-wake disturbance, significantly differentiated cases that transitioned to stage 2 vs those that did not demonstrate transition. Items loading onto this factor, labelled Anergia, included depression severity and aspects of rumination and sleep-wake disturbance that were characterized as introceptive.
CONCLUSIONS: Common dimensions between rumination and sleep-wake disturbance present a detectable trans-diagnostic marker of illness progression in youth, and may represent a target for early intervention.
© 2018 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  clinical staging; rumination; sleep-wake disturbance; trans-diagnostic; youth

Mesh:

Year:  2018        PMID: 30485651     DOI: 10.1111/eip.12757

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  3 in total

1.  Brief Research Report: A Pilot Study of Cognitive Behavioral Regulation Therapy (CBT-REG) for Young People at High Risk of Early Transition to Bipolar Disorders.

Authors:  Jan Scott; Thomas D Meyer
Journal:  Front Psychiatry       Date:  2021-01-22       Impact factor: 4.157

Review 2.  Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary literature review and agenda for future research from the ISBD task force on chronobiology.

Authors:  Michael J McCarthy; John F Gottlieb; Robert Gonzalez; Colleen A McClung; Lauren B Alloy; Sean Cain; Davide Dulcis; Bruno Etain; Benicio N Frey; Corrado Garbazza; Kyle D Ketchesin; Dominic Landgraf; Heon-Jeong Lee; Cynthia Marie-Claire; Robin Nusslock; Alessandra Porcu; Richard Porter; Philipp Ritter; Jan Scott; Daniel Smith; Holly A Swartz; Greg Murray
Journal:  Bipolar Disord       Date:  2021-12-10       Impact factor: 5.345

Review 3.  Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force.

Authors:  Ralph Kupka; Anne Duffy; Jan Scott; Jorge Almeida; Vicent Balanzá-Martínez; Boris Birmaher; David J Bond; Elisa Brietzke; Ines Chendo; Benicio N Frey; Iria Grande; Danella Hafeman; Tomas Hajek; Manon Hillegers; Marcia Kauer-Sant'Anna; Rodrigo B Mansur; Afra van der Markt; Robert Post; Mauricio Tohen; Hailey Tremain; Gustavo Vazquez; Eduard Vieta; Lakshmi N Yatham; Michael Berk; Martin Alda; Flávio Kapczinski
Journal:  Bipolar Disord       Date:  2021-07-23       Impact factor: 5.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.